Search hospitals > Kansas > Mission
University of Kansas Clinical Research Center
Claim this profileMission, Kansas 66205
Global Leader in Skin Cancer
Global Leader in Uterine Tumors
Conducts research for Cancer
Conducts research for Stomach Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
152 reported clinical trials
47 medical researchers
Summary
University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Skin Cancer, Uterine Tumors, Cancer, Stomach Cancer, T-Lymphoblastic Leukemia/Lymphoma and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 590 conditions. There are 47 research doctors associated with this hospital, such as Jun Zhang, Chao H. Huang, Anwaar Saeed, and Jeffrey Statland.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Uterine Tumors
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Jun ZhangHouston Methodist Hospital5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
28 reported clinical trials
43 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
35 drugs studied
Anwaar SaeedUniversity of Kansas Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Stomach Cancer
20 reported clinical trials
37 drugs studied
Jeffrey StatlandUniversity of Kansas Medical Center2 years of reported clinical research
Expert in Muscular Dystrophy
Studies Duchenne Muscular Dystrophy
20 reported clinical trials
19 drugs studied
Clinical Trials running at University of Kansas Clinical Research Center
Lung Cancer
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Colorectal Cancer
Bladder Cancer
Uterine Tumors
Bladder Carcinoma
Cancer
Skin Cancer
Kidney Cancer
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria
Iadademstat + Atezolizumab/Durvalumab
for Small Cell Lung Cancer
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.
Recruiting1 award Phase 1 & 25 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Kansas Clinical Research Center?
University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Skin Cancer, Uterine Tumors, Cancer, Stomach Cancer, T-Lymphoblastic Leukemia/Lymphoma and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 590 conditions. There are 47 research doctors associated with this hospital, such as Jun Zhang, Chao H. Huang, Anwaar Saeed, and Jeffrey Statland.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.